ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Epidemiology"

  • Abstract Number: 2050 • ACR Convergence 2024

    Clinical Enthesitis Concerns Half the Patients with Psoriatic Arthritis, Is More Frequent in Trials Than in Observational Studies and Is Assessed Heterogeneously: A Systematic Review with Meta-analysis of 84,262 Patients from 212 Studies

    caroline pignon1, Laure Gossec2, Bruno Fautrel3, Clementina López Medina4 and Noemie bibas5, 1Faculté de médecine Créteil, PARIS, France, 2Sorbonne Université, Paris, France, 3INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, 4Reina Sofia University Hospital, Cordoba, Spain, 5Sorbonne Université, paris

    Background/Purpose: Enthesitis is considered a hallmark of psoriatic arthritis (PsA), however data on the frequency and consequences of enthesitis are conflicting. To analyze clinical enthesitis in…
  • Abstract Number: 2469 • ACR Convergence 2024

    Machine Learning Identifies Oesophageal Symptoms as a New Red Flag for for Very Early Diagnosis of Systemic Sclerosis (VEDOSS): A EUSTAR Analysis

    Stefano Di Donato1, Vishal Kakkar2, Silvia Bellando-Randone3, Marco Matucci-Cerinic4 and Francesco Del Galdo2, and EUSTAR collaborators, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 2University of Leeds, Leeds, United Kingdom, 3University of Florence, Florence, Florence, Italy, 4University San Raffaele Milano, Milano, Milan, Italy

    Background/Purpose: The analysis of the EUSTAR Very Early Diagnosis of Systemic Sclerosis (VEDOSS) study has identified the risk of progression to fulfil 2013 ACR/EULAR classification…
  • Abstract Number: 2679 • ACR Convergence 2024

    Predictors of Fracture in SLE: A Longitudinal Cohort Study

    Kristen Chao1, Andrea Fava2, Daniel Goldman3, Laurence Magder4 and Michelle Petri3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins University School of Medicine, Timonium, MD, 4University of Maryland, Baltimore, Baltimore, MD

    Background/Purpose: Fractures are one of the most common damage items in the SLICC/ACR Damage Index. Although commonly attributed to corticosteroid use, the complexity of ways…
  • Abstract Number: 0129 • ACR Convergence 2024

    The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on Antiphospholipid Syndrome, a Prospective 24- Week Study

    Qiang Shu1, Qing Zuraw2, Xiaoyu Zhang3, Guillermo Pons-Estel4, Shuning Sun5, Qincheng Che1, Xinyu Li6, Jie Li6 and Qi Liu6, 1Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan, China; Qilu Hospital, Cheeloo College of Medicine, Shandong University, Rheumatology, Jinan, China, Jinan, China (People's Republic), 2RemeGen Biosciences, Inc., South San Francisco, China (People's Republic), 3Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan China, Beijing, China, 4Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, 5Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan, China; Qilu Hospital, Cheeloo College of Medicine, Shandong University, Pheumatology, Jinan, China, Jinan, China (People's Republic), 6Qilu Hospital, Jinan, China (People's Republic)

    Background/Purpose: Antiphospholipid syndrome (APS) is a challenging disease to treat and lack effective therapies. Rituximab (RTX) can deplete CD20+ peripheral B cells. Telitacicept (TA) is…
  • Abstract Number: 0161 • ACR Convergence 2024

    Cross Country Burden of Osteoarthritis in Latin America and Caribbean from 1990-2021: A Comparative and Consistent Benchmarking Analysis for the Global Burden of Disease Study 2022

    malay rathod1, Eva Kalra2, Rafael Sanchez-Dopazo,3, Janmay Vala4, Saif Syed5, Akhilesh Sharma6, Ashwinikumar Shandilya7, Asmita Gera8, Mohit Lakkimsetti9, Juhi Patel10, VISHRANT AMIN11 and Hardik Desai12, 1Monmouth Medical Center, Rutgers University, Ewing, NJ, 2Trident Medical Cente, Charleston, SC, 3Larkin Community Hospital Palm Springs Campus, Hialeah, FL, 4Terna Medical College, Navi Mumbai, Maharashtra, India, 5Royal college of Surgeons,Dublin,Ireland, Dublin, Dublin, Ireland, 6Adesh Institute of Medical Sciences and Research, Bhatinda, India, 7Rural Medical college. Pravara institute of medical sciences., Ahmednagar, India, 8Tianjin medical University, Tianjin, China, Tianjin, Tianjin, China (People's Republic), 9Mamata Medical College,Khammam, Khammam, Telangana, India, 10GMERS MEDICAL COLLEGE VALSAD, 382330, Gujarat, India, 11GMERS MEDICAL COLLEGE VALSAD, Ahmedabad, India, 12Gujarat Adani Institute of Medical Sciences, Bhuj, India

    Background/Purpose: Osteoarthritis (OA) poses a significant and escalating health challenge across Latin America and the Caribbean (LAC), driven by demographic shifts, lifestyle factors, and varying…
  • Abstract Number: 0434 • ACR Convergence 2024

    Pregnancy Outcomes of Biosimilars and Non-TNF Inhibitor Biologic Disease-Modifying Antirheumatic Drugs: A Scoping Review

    Vienna Cheng1, Neda Amiri2, Vicki Cheng1, Ursula Ellis3, Jacquelyn J. Cragg1, Mark Harrison1 and Mary A. De Vera1, 1University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, 2University of British Columbia, Faculty of Medicine, Vancouver, BC, Canada, 3University of British Columbia, Woodward Library, Vancouver, BC, Canada

    Background/Purpose: Biosimilar and biologic (b) DMARDs have revolutionized rheumatic disease management in the recent decades. As these drugs become introduced, it is important to understand…
  • Abstract Number: 0717 • ACR Convergence 2024

    Associations Between Calendar Time and Age at Diagnosis with Mortality in a National Cohort of Veterans with ANCA-Associated Vasculitis from 2001-2020

    Jennifer Hanberg1, Svetlana Eden2, Amy Anderson-Mellies2, Suman Kundu2, Matthew Freiberg2, Zachary Wallace3 and Evelyn Hsieh4, and the Veterans Aging Cohort Study Project Team, 1Brigham and Women's Hospital, Boston, MA, 2Vanderbilt University Medical Center and Tennessee Valley VA, Nashville, TN, 3Massachusetts General Hospital, Newton, MA, 4Yale School of Medicine / VA Connecticut Healthcare System, West Haven, Connecticut, New Haven, CT

    Background/Purpose: It is not clear whether advances in ANCA-associated vasculitis (AAV) management between 2001-2020 have translated to improvement in population-level outcomes, including among older adults.…
  • Abstract Number: 0991 • ACR Convergence 2024

    Comparing the Prevalence of Sarcoidosis in Canadian Rural, Urban, and Farming Populations

    Varinder Hans1, Don Voaklander1, C. Allyson Jones2 and Elaine Yacyshyn2, 1University of Alberta, Edmonton, Canada, 2University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Sarcoidosis is a granulomatous inflammatory response thought to be due to a dysregulated immune response to environmental antigens.1 The prevalence of sarcoidosis varies geographically.…
  • Abstract Number: 1095 • ACR Convergence 2024

    The Incidence of Gout Among Individuals with Hyperuricemia over Time – an Insight from a Nationwide Cohort Study

    Shay Brikman1, Amir Bieber2, Liel Serfaty, MA3, Ran Abuhasira, MD, PhD4, Nadav Rappoport5 and Naomi Schlesinger6, 1Emek Medical Center, Afula, Israel, 2Emek Medical Center, Clalit Health Services, Raanana, Israel, 3Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, 4Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, 5Ben-Gurion University of the Negev, Beer-Sheva, Israel, 6University of Utah, Salt Lake City, UT

    Background/Purpose: Hyperuricemia is considered the most important risk factor for developing Gout, the most common adult inflammatory arthritis. Hyperuricemia is defined by a serum urate…
  • Abstract Number: 1353 • ACR Convergence 2024

    Association Between Frailty and Incident Cancer in Newly Diagnosed Rheumatoid Arthritis

    Bhavik Bansal1, Laura Gold2, Katherine Wysham3, James Andrews4, Alexa Meara5, Carolyn Presley6, Elad Sharon7, Jiha Lee8, Jennifer Barton9, Una Makris10 and Namrata Singh11, 1All India Institute of Medical Sciences, New Delhi, Delhi, India, 2University of Washington, Seattle, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4University of Alabama at Birmingham, Birmingham, AL, 5The Ohio State University Wexner Medical Center, COLUMBUS, OH, 6The Ohio State Medical Center, Columbus, OH, 7Dana Farber Cancer Institute, Boston, MA, 8University of Michigan, Ann Arbor, MI, 9VA Portland Health Care System/OHSU, Portland, OR, 10UT Southwestern Medical Center and Dallas VA, Dallas, TX, 11University of Washington, Bellevue, WA

    Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk of cancer, but the underlying risk factors remain poorly understood. Frailty is linked to an…
  • Abstract Number: 1756 • ACR Convergence 2024

    What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an IL-17A Inhibitor

    Jette Heberg1, Stylianos Georgiadis2, Marion Pons3, Anne Gitte Loft4, Brigitte Michelsen5, Louise Linde3, Daniela DiGuiseppe6, Simon Horskjær Rasmussen3, Mehrdad Kazemi3, Gary Macfarlane7, Gareth Jones7, Karin Laas8, Sigrid Vorobjov9, Isabel Castrejon10, Ziga Rotar11, Katja Perdan-Pikmajer11, Ladislav Šenolt12, Jana Baranová13, Bente Glintborg14, Adrian Ciurea15, Miguel Bernardes16, Paula Valente17, Bjorn Gudbjornsson18, Gerdur Gröndal18, Gunnstein Bakland19, Catalin Codreanu20, Corina Mogosan20, Florenzo Iannone21, Roberto Caporali22, Johan Karlsson Wallman23, Vappu Rantalaiho24, Ritva Peltomaa25, Karel Pavelka26, Pavel Horak27, Diogo Esperança Almeida28, Sara Dias Rodrigues29, Lykke Oernbjerg2, Mikkel Ostergaard30 and Merete Hetland31, 1Rigshospitalet Glostrup, København V, Denmark, 2Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, 3Rigshospitalet Glostrup, Glostrup, Denmark, 4Aarhus University Hospital and Aarhus University, Horsens, Denmark, 5Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, 6Karolinska Institutet, Stockholm, 7University of Aberdeen, Aberdeen, United Kingdom, 8East-Tallinn Central Hospital, Tallinn, Estonia, 9National Institute for Health Development, Tallinn, Estonia, 10Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, 11University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, 12Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 13Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, 14DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, 15University Hospital Zurich, Zürich, Switzerland, 16São João Hospital Center and FMUP, Lisboa, Portugal, 17Rheumatology Department, Hospital de São Sebastião, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal, 18Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, 19Department of Rheumatology, University Hospital North Norway, Tromsø, Norway, 20University of Medicine and Pharmacy, Bucharest, Romania, 21Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, 22Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, 23Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, 24Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, 25Helsinki University Hospital and University of Helsinki, Helsinki, Finland, 26Institute of Rheumatology and Charles University, Praha, Czech Republic, 273rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic, 28Hospital de Braga, Braga, Portugal, 29Serviço de Reumatologia, Hospital Egas Moniz, Unidade Local de Saúde Lisboa Ocidental, Lisboa, Portugal, 30Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, 31Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark

    Background/Purpose: Tumour necrosis factor inhibitors (TNFi) and Interleukin-17Ai inhibitors (IL-17Ai) have shown effectiveness in achieving low disease activity (LDA) in patients with axial spondyloarthritis (axSpA).…
  • Abstract Number: 1893 • ACR Convergence 2024

    Hydroxychloroquine Use in Early Pregnancy and Risk of Preterm Delivery in a Californian Cohort of Lupus Pregnancy

    Amadeia Rector1, Emily Liu2, Miranda Cantu3, Eliza Chakravarty4, Maurice Druzin5, Gary Shaw6, Michael Weisman7, Monique Hedderson2 and Julia Simard8, 1Stanford University, San Francisco, CA, 2Kaiser Permanente Division of Research, Oakland, CA, 3Patient partner, Portage, MI, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Stanford University School of Medicine, Stanford, CA, 6Stanford University School of Medicine, Stanford, 7Stanford University, Los Angeles, CA, 8Stanford School of Medicine, Stanford, CA

    Background/Purpose: Preterm delivery (PTD) occurs 2-3 times more frequently in patients with systemic lupus erythematosus (SLE) compared to the general obstetric population. Hydroxychloroquine (HCQ), a…
  • Abstract Number: 2055 • ACR Convergence 2024

    Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)

    Laura Kopplin1 and Karen Armbrust2, 1Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, 2Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN

    Background/Purpose: Scleritis is a rare, potentially vision threatening ocular inflammatory disease.  30-40% of scleritis is associated with systemic autoimmune diseases with reports of worse visual…
  • Abstract Number: 2489 • ACR Convergence 2024

    Avacopan for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in a Real-World Setting

    Naomi Patel1, Ana Fernandes1, Andrew King1, Shruthi Srivatsan1, Colebrook Johnson1, Zachary Williams1, Madison Negron1, Caleb Bolden1, Miao Lin1, Bohang Jiang1, Sam Oh2, Darcy Trimpe2, Sushmitha Inguva2 and Zachary Wallace3, 1Massachusetts General Hospital, Boston, MA, 2Amgen Inc., Thousand Oaks, CA, 3Massachusetts General Hospital, Newton, MA

    Background/Purpose: Avacopan is approved in the US for use in adults with severe active GPA or MPA alongside background immunosuppression. Efficacy and safety data on…
  • Abstract Number: 2681 • ACR Convergence 2024

    Association of Social Determinants of Health with Systemic Lupus Erythematosus in the United States: Nationally Representative Estimates for 2017-2021

    Ami Vyas, Steven Cohen and Christine Eisenhower, University of Rhode Island, Kingston, RI

    Background/Purpose: Careful assessment of individuals’ social determinants of health (SDOH) that affect systemic lupus erythematosus (SLE) is crucial, as such evidence will improve care and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 46
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology